Compare DexCom, Inc. (DXCM) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? DexCom, Inc. trades at $77.91 (market cap $28.06B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.87. The key difference: DexCom, Inc. is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | MSTU | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $106.80 |
52-Week Low | $54.84 | $1.46 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
MSTU trades at $1.845, down 6.82% in the last session, reflecting significant volatility. Technical indicators show a bearish moving average signal but neutral oscillators, with key support and resistance clustered at $2. Financial ratios are unavailable, and recent news highlights extreme losses, including a 98% decline from November 2024 levels per 24/7 Wall Street on 2026-06-11.
The outlook remains highly speculative with substantial downside risk due to leveraged exposure to MicroStrategy's performance. Investors face potential for rapid erosion of capital amid volatility, while any recovery hinges on MicroStrategy's stock rebound. Caution is warranted given the fund's track record of severe losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
